Financial analysts have said that 2022 may have been the worst year for hospital finances in decades. This year looks like it will be yet another year of financial underperformance, with rural providers in especially dire circumstances.
Withings announced that it is developing a miniaturized platform that can analyze urine at home. The device, called U-Scan, sits within a toilet bowl and assesses specific biomarkers found in urine.
Atacicept, a Vera Therapeutics drug in development for the rare kidney disease immunoglobulin A nephropathy, is on its way to a pivotal test after achieving the main goal of a mid-stage clinical trial. But the results still fall short of data recently reported by a competitor that is addressing the same disease target.
A recent study published in BMC Psychiatry found that depression and anxiety decreased at similar rates between patients using telehealth and patients receiving in-person care.
Gilead Sciences is building up its autoimmune disease drug pipeline by turning to EVOQ Therapeutics, a startup with technology that takes a novel approach to restoring immune tolerance. For EVOQ, the Gilead deal is its second with a big pharma company.
By allowing study teams to design and conduct more inclusive and/or relevant studies, real-world data can enhance the standard of care and ultimately improve patient outcomes.
Possible strategies for employers to reduce disparities include addressing social determinants of health, improving care navigation, leveraging virtual care and upgrading plan offerings, the authors of a Harvard Business Review report said.
Artificial intelligence is anexciting area of technology innovation for healthcare and life sciences. Download this free eBook to understand how this technology is shaping the future of health and life sciences.
No comments